All In Biotech

Drug Trial Radar · NCT03422653

A Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus (KALM-1)

A Multicenter, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Safety and Efficacy of Intravenous CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus, With a 52-Week Open Label Extension

Last checked: Nov 19, 2026Latest source record: Apr 26, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 378 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

378

Actual

Start

Feb 20, 2018

Primary completion

Apr 6, 2019

Study completion Mar 26, 2020

Sponsor

Lead sponsor
Cara Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Feb 6, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of intravenous (IV) CR845 at a dose of 0.5 mcg/kg administered after each dialysis session. The study includes a 12-week Double-blind Phase and a 52-week Open-label Extension Phase.

Conditions

  • Uremic Pruritus

Interventions

  • CR845 0.5 mcg/kgDrug

    IV medication delivered three times/week

  • PlaceboDrug

    IV medication delivered three times/week

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Reduction of Itch Intensity as Assessed by the Percentage of Patients Achieving an Improvement From Baseline ≥3 Points With Respect to the Weekly Mean of the Daily 24-hour Worst Itching Intensity Numerical Rating Scale (NRS) Score at Week 12Time frame: Week 12

Locations

57 sites in 1 country. Site status is shown where the registry gives one.

  • Cara Therapeutics Study Site

    Homewood, Alabama

  • Cara Therapeutics Study Site

    Huntsville, Alabama

  • Cara Therapeutics Study Site

    Bakersfield, California

  • Cara Therapeutics Study Site 2

    Beverly Hills, California

  • Cara Therapeutics Study Site

    Beverly Hills, California

  • Cara Therapeutics Study Site

    Chula Vista, California

  • Cara Therapeutics Study Site

    Corona, California

  • Cara Therapeutics Study Site

    Escondido, California

  • Cara Therapeutics Study Site

    Fountain Valley, California

  • Cara Therapeutics

    La Mesa, California

  • Cara Therapeutics Study Site

    Long Beach, California

  • Cara Therapeutics Study Site

    Ontario, California

  • Cara Therapeutics Study Site

    Riverside, California

  • Cara Therapeutics Study Site

    Roseville, California

  • Cara Therapeutics Study Site

    San Diego, California

  • Cara Therapeutics Study Site

    San Dimas, California

  • Cara Therapeutics Study Site

    Tarzana, California

  • Cara Therapeutics Study Site

    Denver, Colorado

  • Cara Therapeutics Study Site

    Bridgeport, Connecticut

  • Cara Therapeutics Study Site

    Hartford, Connecticut

  • Cara Therapeutics Study Site

    Middlebury, Connecticut

  • Cara Therapeutics Study Site 1

    Coral Springs, Florida

  • Cara Therapeutics Study Site

    Hialeah, Florida

  • Cara Therapeutics Study Site

    Miami, Florida

  • Cara Therapeutics Study Site

    Miami Gardens, Florida

  • Cara Therapeutics Study Site

    Tampa, Florida

  • Cara Therapeutics Study Site

    Kalamazoo, Michigan

  • Cara Therapeutics Study Site

    Roseville, Michigan

  • Cara Therapeutics Study Site

    Minneapolis, Minnesota

  • Cara Therapeutics Study Site

    Brookhaven, Mississippi

  • Cara Therapeutics Study Site

    McComb, Mississippi

  • Cara Therapeutics Study Site

    Tupelo, Mississippi

  • Cara Therapeutics Study Site

    Kansas City, Missouri

  • Cara Therapeutics Study Site

    Las Vegas, Nevada

  • Cara Therapeutics Study Site

    Las Vegas, Nevada

  • Cara Therapeutics Study Site

    Eatontown, New Jersey

  • Cara Therapeutics Study Site

    Albuquerque, New Mexico

  • Cara Therapeutics Study Site

    Gallup, New Mexico

  • Cara Therapeutics Study Site

    Fresh Meadows, New York

  • Cara Therapeutics Study Site

    Great Neck, New York

Showing 40 of 57 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.